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Abstract
Background
Human T-lymphotropic virus type 1 (HTLV-1) has been discovered in 1980 and has been
linked to tropical spastic paraparesis (HAM/TSP) in 1985 in Martinique. There is no data on
HAM/TSP incidence trends. We report, in the present work, the temporal trends incidence
of HAM/TSP in Martinique over 25 years.
Methods
Martinique is a Caribbean French West Indies island deserved by a unique Neurology
Department involved in HAM/TSP diagnosis and management. A registry has been set up
since 1986 and patients diagnosed for a HAM/TSP were prospectively registered. Only
patients with a definite HAM/TSP onset between 1986 and 2010 were included in the pres-
ent study. The 25-year study time was stratified in five-year periods. Crude incidence rates
with 95% confidence interval (95%CI) were calculated using Poisson distribution for each
period. Age-standardized rates were calculated using the direct method and the Martinique
population census of 1990 as reference. Standardized incidence rate ratios with 95% CIs
and P trends were assessed from simple Poisson regression models. Number of HTLV-1
infection among first-time blood donors was retrospectively collected from the central com-
puter data system of the Martinique blood bank. The HTLV-1 seroprevalence into this popu-
lation has been calculated for four 5-year periods between 1996 and 2015.
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Results
Overall, 153 patients were identified (mean age at onset, 53+/-13.1 years; female:male
ratio, 4:1). Crude HAM/TSP incidence rates per 100,000 per 5 years (95%CI) in 1986–1990,
1991–1995, 1996–2000, 2001–2005 and 2006–2010 periods were 10.01 (6.78–13.28),
13.02 (9.34–16.70), 11.54 (8.13–14.95), 4.27 (2.24–6.28) and 2.03 (0.62–3.43). Age-stan-
dardized 5-year incidence rates significantly decreased by 69% and 87% in 2001–2005 and
2006–2010 study periods. Patients characteristics did not differ regarding 1986–2000 and
2001–2010 onset periods. Between 1996–2000 and 2011–2015 study periods, the HTLV-1
seroprevalence significantly decreased by 63%.
Conclusion
Martinique faces a sudden and rapid decline of HAM/TSP incidence from 2001 in compari-
son to 1986–2000 periods. Reduction of HTLV-1 seroprevalence, that may result from trans-
mission prevention strategy, could account for HAM/TSP incidence decrease.
Author summary
Human T-lymphotropic virus type 1 (HTLV-1) was discovered in 1980 and HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP) was described five years
later in 1985. HAM/TSP is a progressive disabling disorder characterized by spastic para-
paresis with bladder and bowel dysfunction that constitutes a significant public health
problem in endemic areas. Up to date, there is no efficiency treatment of HAM/TSP and
prevention of HTLV-1 transmission is critical to limit the disease spreading throughout
communities. In the present 25-year-study time, we report a significant decrease of
HAM/TSP incidence estimated more than 70% in early 2000 compared to 1986–2000
period in Martinique a French West Indies Island. We found a trend to a significant older
age at onset after 2000 (52.1 years versus 57.5 years, p = 0.06) that may reflect an age
cohort effect and that could be indicative of a rapid decrease in HTLV-1 seroprevalence.
We showed a significant decline in HTLV-1 infection among first-time blood donors
between 1996–2000 and 2011–2015 study periods. Thus, probable HTLV-1 seropreva-
lence decrease secondary to HTLV-1 antibodies screening in blood donors and pregnant
women and to iterative information campaigns could partly account for HAM/TSP inci-
dence decline. This study emphasizes the importance of prevention strategies to control
HAM/TSP development in HTLV-1 endemic areas.
Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is associated with many diseases including
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is estimated that
about 10–20 million people are infected with HTLV-1 throughout the world [1].
Whereas HTLV-1 seroprevalence is unknown for 80% of world population [2], data are
available in endemic regions and ranges from less than 1 per 10,000 people to more than 10%.
The highest rates are found in Japan, Brazil, Colombia, the Caribbean islands, Equatorial
Africa, Northeast Australia and Papua New Guinea [3]. Routes of infection include unscreened
transfusion [4,5] and organ transplants [6], sharing of needles or syringes with infected
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subjects, sexual contact [7] and breast-feeding [8,9]. The predominant HTLV-1 horizontal
transmission through condom-less sex leads to dramatic seroprevalence regional variations
even in high endemic area. Prevalence in population increases steadily with age and is higher
in females [10].
The risk of developing HAM/TSP in HTLV-1 infected individuals has been assessed and
deeply varies between studies and ethnic groups. In southern Japan the lifetime risk is 0.25%
[11] while the 10-year risk reaches 5.3% in a Brazilian cohort [12]. Whereas, HTLV-1 sero-
prevalence rate is widely reported [3], no data is available on HAM/TSP incidence in general
population and in defining area.
We report in the present study the incidence of HAM/TSP and its temporal trends, in the
population of Martinique, French West Indies, over a 25-year period from 1986 to 2010. Tem-
poral trends in HTLV-1 infection prevalence among first-time blood donors between 1996
and 2015 have also been calculated.
Methods
Study design and population
Martinique is one of the most highly developed islands in the Caribbean, classified high (41st)
in terms of global human development at the world level. The population steadily increased
between 1982 (328,566) and 2010 (394,171). The great majority (95%) of the population is
Afro-Caribbean.
Our Neurology department, located at the University Hospital of Martinique, constitutes
the only neurological facility for patients in Martinique. It is highly involved in HAM/TSP
diagnosis and management since the original description of the association between HTLV-1
and HAM/TSP [13]. The unique virology department is included in the University hospital.
The island is also deserved by 3 neurological rehabilitation centers that work closely with the
Neurology department. Since HAM/TSP diagnosis requires cerebrospinal fluid analysis, prac-
titioners and other hospitals use to refer suspected cases to our department. Between 1986 and
2014, the global health care networks implemented for HTLV-1 infection experienced only
slight changes. The most significant changes related to care provided in the Neurology and
Rehabilitation departments for HAM/TSP symptoms that have improved between 1986 and
2014.
To reduce HTLV-1 transmission among Martinique population, prevention programs were
implemented in the early nineties. Blood-donor and organ-donor screening was systematically
introduced. Blood and organ donations are invariably rejected if HTLV-1 is detected. Simi-
larly, antenatal screening was implemented to prevent mother-to-child transmissions of
HTLV-1 by breastfeeding avoidance. Information campaigns were regularly performed
encouraging the use of condom to prevent sexually transmitted infection including HIV and
HTLV-1.
The present study is based on a retrospective analysis on data prospectively collected
between 1986 and 2015 in a dedicated registry. Patients with a HAM/TSP onset between 1986
and 2010 were considered.
Case ascertainment and assessment of HAM/TSP patients
A registry has been set up since January 1986 and was still in progress in June 2015. HAM/TSP
characteristics were collected carefully and continuously. Physicians involved in HTLV-1 dis-
eases including neurologists, rehabilitation physicians, ophthalmologists, hematologists and
dermatologists reported patients included in the registry. On a yearly basis, a cross-analysis of
virology and clinical database was performed.
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A standardized case report form has been elaborated and collected the demographic data,
the medical history, the clinical symptoms, the initial symptoms (gait impairment or urinary
disturbances), the onset-to-diagnosis delay and the CSF analysis. The year of first symptoms,
such as stiffness or weakness in the legs or urinary disturbances, defined the year of HAM/TSP
onset.
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-enhanced blood
by density gradient centrifugation. Real Time TaqMan PCR was performed on DNA extracted
from dry pellets of 106 cells stored at -80˚C after preparation from blood sample PBMCs. For-
ward and reverse primers for HTLV-I DNA quantitation: SK110 (50-CCCTACAATCCAACC
AGCTCAG-30, HTLV-I nucleotide 4758–4779; SK111 (50-GTGGTGAAGCTGCCATCGGGT
TTT-30, HTLV-I nucleotide 4943–4920). Internal HTLV-I TaqMan probe: 50CTTTACTGAC
AAACCCGACCTACCCATGGA-30; Located between position 4829 and 4858 of the HTLV-I
genome, and carried a 50 reporter dye FAM (6-carboxy fluorescein) and a 30 quencher dye
TAMRA (6-carboxy tetramethyl rhodamine). Forward and reverse primers for human albu-
min DNA quantification: Alb-S (50-GCTGTCATCTCTTGTGGGCTGT-30) and Alb-AS (50-A
AACTCATGGGAGCTGCT GGTT-30). Alb TaqMan probe (50-FAM-CCTGTCATGCCCA
CACAAATCTC TCC-TAMRA-30) were used as described previously [14]. Results were
expressed as the number of HTLV-1 copies per 106 PBMCs.
For the purpose of the present study, each chart was reviewed and HAM/TSP diagnosis
was defined according to an updated staged approach to the World Health Organization
criteria [15]. Only definite HAM/TSP was retained in the presence of the following: 1) A
non-remitting progressive spastic paraparesis with sufficiently impaired gait to be perceived
by the patient. Sensory symptoms or signs can be present. When present, they remain subtle
and without a clear-cut sensory level. Urinary and anal sphincter signs or symptoms can
be present; 2) Presence of HTLV-1 antibodies in serum and CSF confirmed by western blot
analysis and/or a positive PCR for HTLV-1 in blood and/or CSF; 3) Systematic spinal cord
imaging and extensive biological work-up ruled out differential diagnosis of progressive
paraparesis.
HTLV-1 seroprevalence assessment among blood donors
In Martinique, all blood donations are performed in the center for blood transfusion (Etablis-
sement Franc¸ais du Sang). Demographic characteristics of all first-time blood donors tested
positive for HTLV-1 were retrospectively collected from the central computer data system of
the blood bank. Only donors tested positive with ELISA assay and confirmed with Western
blot assay were retained. Data were available for the 20-year period from January 1, 1996 and
December 31 2015. Characteristics of all donors were not available for the present study.
Ethical statement
The present research was conducted according to the principles of the declaration of Helsinki.
In 1995, a hospital ethic committee (Comite´ Consultatif de Protection des Personnes dans la
Recherche Biome´dicale) was constituted and approved the HAM/TSP registry. Between 1986
and 1994, only oral informed consents were obtained whereas all patients included in the reg-
istry after 1994 have given their written informed consent. After standardized information, the
oral consent was obtained and collected in the patient’s chart. The hospital ethic committee
allowed retrospectively oral consents for 1986–1994 period. For child inclusion participant, a
parent has provided informed consent on the child’s behalf. Analysis was performed on anon-
ymized data to ensure confidentiality.
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Statistical analysis
Due to the small number of events per year, the 25-year study time, from January 1, 1986 to
December 31, 2010, was stratified in five-year periods for HAM/TSP incidence analysis. Simi-
larly, the 20-year study time, from January 1, 1996 to December 31, 2015, for HTLV-1 sero-
prevalence in first-time blood donors was stratified in four 5-year periods.
The numerator for calculation of incidence rate was the number of HAM/TSP patients with
a disease onset in the defining period. The denominator was based on data provided by French
National Institute for Statistical and Economic Studies (www.insee.fr). By convention, the pop-
ulation of the last year of each defined period was considered for calculation. Crude incidence
rates with 95% confidence intervals (95%CIs) were calculated using Poisson distribution for
each period. Age-standardized rates were calculated using the direct method and the Marti-
nique population census of 1990 as reference. The Martinique population census of 1990 con-
stituted the denominator to calculate HAM/TSP incidence for the first study period 1986–
1990. Then populations of 1995, 2000, 2005 and 2010 were used for 1991–1995, 1996–2000,
2001–2005 and 2006–2010 study periods. Standardized incidence rate ratios with 95% CIs and
P trends were assessed from simple Poisson regression models. P for trend was used to either
support or reject a linear trend in HAM/TSP standardized incidence rates from the first to the
last study period.
Seroprevalence of HTLV-1 within the four periods was expressed as number of seropositive
HTLV-1 subjects per one hundred new blood donors. A binomial analysis was used for 95%
CI of seroprevalence rates. The first study period (1996–2000) was used as reference to calcu-
late the odds ratio of seroprevalence with 95%CI in the four study periods.
The χ2 test or Fisher-exact test, as appropriate, and Student t test or Mann-Whitney test
were used to examine differences in nominal and continuous values. All analyses were per-
formed in SAS 9.3 (SAS Institute, Inc, Cary, NC) and MS Excel software.
Results
Between January 1986 and June 2015, 326 HAM/TSP patients were included in our registry. We
excluded 84 patients who met the diagnosis of probable HAM/TSP according to WHO criteria.
Among the 242 definite HAM/TSP patients, 89 were excluded regarding their year of onset before
1986 (83) or after 2010 (6). Eventually, 153 definite HAM/TSP patients experienced a disease
onset over the 25-year study period. The mean age at onset was 53 ± 13 years and females
Table 1. HAM/TSP characteristics in the whole cohort.
Whole cohort
N = 153
Age at Onset
Mean ± SD (years)
Median (years)
Range
53±13.1
55
14–77
Sex Ratio F/M (% of female) 122/31 (79.7)
Gait Impairment Onset, n (%) 123 (80.4)
Blood transfusion before 1990, n (%) 32 (20.9)
Onset-to-Diagnosis Delay,
Mean ± SD (years)
Median (years)
Range
4.9±3.2
3
0–14
Proviral load (HTLV-1 copies per 106 PBMCs) 110,794±108,017
PBMCs: peripheral blood mononuclear cells; SD: Standard Deviation.
https://doi.org/10.1371/journal.pntd.0006304.t001
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predominated (79.7%). Patients experienced gait impairment as first symptoms in 86% and the
median onset-diagnosis delay was 3 years. Patient’s characteristics are summarized in Table 1.
The Fig 1 shows the number of HAM/TSP diagnosis per year over the 25-year study period.
Trends in HAM/TSP incidence
The 5-year crude incidence rates (95%CI) per 100,000 in 1986–1990, 1991–1995, 1996–2000,
2001–2005 and 2006–2010 study periods are reported in Table 2. Between 1986 and 2000 rates
were stable and ranged from 10.01 (6.78–13.28) to 13.02 (9.34–16.7) whereas rates declined in
the two earliest periods 2001–2005 and 2006–2010, 4.27 (2.24–6.28) and 2.03 (0.62–3.43). Age-
standardized incidence rates on Martinique population census of 1990 (used for 1986–1990
study period) significantly decreased by 69% and 87% in 2001–2005 and 2006–2010 study peri-
ods (Table 2).
Trends in HAM/TSP characteristics
Regarding HAM/TSP incidence rate decline from 2001, we compared patient’s characteristics
between the two groups whose disease onset was in 1986–2000 and 2001–2010 periods.
Fig 1. Number of HAM/TSP diagnosis per year over the 25-year study period.
https://doi.org/10.1371/journal.pntd.0006304.g001
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Table 3 compares the characteristics of HAM/TSP patients with a disease onset in 1986–
2000 and in 2001–2010.
Sex ratio, initial symptoms, onset-to-diagnosis delay and history of blood transfusion before
1990 were comparable between the two groups. We found a trend to significance for an older
age at onset in 2001–2010 incident cases.
Level of HTLV-1 in PBMC was available for 123 out of 153 patients. The mean level of
HTLV-1 proviral load did not differed between the two study periods.
Trends in HTLV-1 infection among first-time blood donors
Table 4 shows the prevalence of HTLV-1 infection in first-time blood donors within the four
5-year study periods. Seropositive male subjects were statistically younger in the first study
period compared to the 3 earliest periods. Compared to the first study period (1996–2000),
HTLV-1 infection frequencies were significantly lower in the earliest study periods (2001–
2005, 2006–2010, 2011–2015) as illustrated by the absence of 95%CI range limits overlap.
Between 1996–2000 and 2011–2015 study periods, the HTLV-1 seroprevalence significantly
Table 2. Crude and age-standardized 5-year incidence rates and rate ratio of HAM/TSP in Martinique between 1986 and 2010.
Study
Periods
Estimated Population
at Risk
Events, n Crude 5-year Incidence Rate
(95%CI)
1986–1990 age-standardized 5-year
incidence rates (95%CI)
Standardized Incidence Rate
Ratio (95%CI)
1986–1990 359,579 36 10.01 (6.78–13.28) 10.01 (6.78–13.28) 1
1991–1995 368,735 48 13.02 (9.34–16.70) 11.93 (8.61–15.25) 1.19 (0.87–1.55)
1996–2000 381,325 44 11.54 (8.13–14.95) 10.37 (7.28–13.47) 1.04 (0.91–1.13)
2001–2005 397,727 17 4.27 (2.24–6.28) 3.13 (1.64–4.62) 0.31 (0.17–0.51)
2006–2010 394,171 8 2.03 (0.62–3.43) 1.34 (0.41–2.27) 0.13 (0.09–0.18)
CI indicates Confidence Interval
The 1986-1990-study period was used as reference for the standardized incidence rate ratio calculation.
According to simple Poisson regression model, P for trend of age-standardized 5-year incidence rates over the study periods was calculated as <0.01.
https://doi.org/10.1371/journal.pntd.0006304.t002
Table 3. HAM/TSP characteristics according a disease onset in 1986–2000 and 2001–2010 periods.
1986–2000
N = 128
2001–2010
N = 25
p
Age at Onset
Mean ± SD (years)
Median (years)
Range
52.1±13.5
55
14–77
57.7±9.6
57
42–72
0.067
Sex Ratio F/M (% of female) 104/24 (81.2) 18/7 (72) 0.43
Gait Impairment Onset, n (%) 104 (81.2) 19 (76) 0.7
Blood transfusion before 1990, n (%) 28 (21.9) 4 (16) 0.59
Onset-to-Diagnosis Delay,
Mean ± SD (years)
Median (years)
Range
5.1±3.1
3
0–14
4.2±3.5
3
1–8
0.45
Proviral load (HTLV-1 copies per 106 PBMCs) 107,954±104,248 135,880±140,000 0.48
Characteristics of 1986–2000 and 2001–2010 study periods were compared using Khi-2 test except for age (Student t-
test), Blood transfusion (Fisher’s exact test) and Proviral load (Mann-Whitney test).
Level of HTLV-1 proviral load was missing for 30 patients, 23 HAM/TSP patients with an onset within 1986–2000
study period and 7 within 2001–2010 study period. The other variables were available for all patients.
https://doi.org/10.1371/journal.pntd.0006304.t003
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decreased by 63%, 67% and 61% in the whole, female and male population of first-time blood
donors respectively.
Discussion
Over 25 years, 1986–2010, our study reports a significant decrease of new definite HAM/TSP
cases. Whereas the crude 5-year incidence rates remained stable between 1986 and 2000, rang-
ing from 10.1 to 12.2/100,000, the rates rapidly decline between 2001 and 2010, ranging from
3.2 and 2.9/100,000. The age-standardized 5-year incidence rates exhibit a dramatic decrease
by 70% from 2001 and reaching 87% for 2006–2010 periods.
In accordance with previous studies, the age at onset of HAM/TSP patients was around 50
years old [16–18]. We found a trend to a significant older age at onset after 2000 (52.1 versus
57.5, p = 0.06) that may reflect an age cohort effect and that could be indicative of a rapid
decrease in HTLV-1 seroprevalence. As usually reported, females are highly predominant in
Martinique HAM/TSP patients [19] and the proportion does not differ between 1986–2000
and 2001–2010 onset cases. Blood transfusion constitutes a usual infection route and a study
from Japan showed a 16% decrease in the incidence of HAM/TSP 2 years after blood-donor
screening implementation [20]. We did not observe any differences in blood transfusion his-
tory frequencies between patients whose onset was before or after 1990. As previously
reported, [19] initial neurological symptoms were predominantly gait impairment without any
difference between the two onset groups. The median delay between onset and diagnosis was
stable over the study time and was set at 3 years.
In 1989, HTLV-1 seroprevalence was appraised at 2.2% in the general population of Marti-
nique [21], while it was estimated to 1.93% among pregnant women [22] and to 0.4% among
blood donors cohort in the mid-nineties [23]. Although no relevant data are available on
Table 4. Prevalence of HTLV-1 infection among first-time blood donors by genders in the four 5-year study periods.
Study Periods 1996–2000 2001–2005 2006–2010 2011–2015 p
Whole subjects
First-time Blood Donors, n 11932 12276 12948 9727
HTLV-1 Seropositive, n 67 46 33 20
Age (y), Mean±SD 38.7±11.9 43.9±11.2 43.3±13.7 44.1±12.3 0.025
Seroprevalence, %, (95%CI) 0.56 (0.42–0.69) 0.38 (0.27–0.48) 0.26 (0.17–0.34) 0.21 (0.12–0.30)
Odds Ratio (95%CI) 1 0.67 (0.46–0.98) 0.45 (0.30–0.68) 0.37 (0.22–0.61)
Female
First-time blood donors, n 5713 6630 7140 5487
HTLV-1 Seropositive, n 41 29 24 13
Age (y), Mean±SD 40.6±11.4 44.1±11.3 43.7±14.6 42.5±15.4 0.35
Seroprevalence, %, (95%CI) 0.72 (0.50–0.94) 0.44 (0.28–0.60) 0.34 (0.20–0.47) 0.24 (0.11–0.37)
Odds Ratio (95%CI) 1 0.61 (0.38–0.98) 0.47 (0.28–0.78) 0.33 (0.18–0.62)
Male
First-time blood donors, n 6219 5646 5808 4240
HTLV-1 Seropositive, n 26 17 9 7
Age (y), Mean±SD 35.6±12.2 43.6±11.3 42.4±11.6 46.4±5.7 0.028
Seroprevalence, %, (95%CI) 0.42 (0.26–0.58) 0.30 (0.16–0.44) 0.15 (0.05–0.26) 0.17 (0.04–0.29)
Odds Ratio (95%CI) 1 0.72 (0.39–1.33) 0.37 (0.17–0.79) 0.39 (0.17–0.90)
CI indicates Confidence Interval; SD indicates Standard Deviation
Odds ratio were calculated using the 1996–2000 study period as reference
https://doi.org/10.1371/journal.pntd.0006304.t004
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HTLV-1 seroprevalence trends in our general population, infection rates in blood donors were
analyzed over twenty years from 1996 to 2015. Seroprevalence of HTLV-1 infection among
first-time blood donors decreased significantly by 63% between 1996–2000 and 2011–2015
study periods. Seroprevalence decrease may partly account for HAM/TSP incidence decline
and may result from several factors. These include the rapid westernization of life style that
spread through the whole population from the eighties, the systematic screening for HTLV-1
antibodies in volunteer blood donor and pregnant women [16,17] that has been implemented
in the early nineties in Martinique and the iterative information campaigns for HIV and
HTLV-1 prevention that particularly encouraged the use of condoms in the population. Pre-
vention strategy leading to refrain HTLV-1 infected mother to breast fed their children has
demonstrated efficiency in seroprevalence decrease [9]. However, such a dramatic HAM/TSP
incidence decline from 2001 is intriguing. Indeed, individuals aged around 50 years old
between 2001 and 2010 became sexually active before implementation of HTLV-1 transmis-
sion prevention strategy. Additionally, they were all exposed to HTLV-1 contamination
through breastfeeding and were at exposure risk through untested blood transfusion at least
the first 20 years of life. HTLV-1 transmission prevention strategy could not be sufficient to
account for such an early incidence decrease. This raises the question of a co-factor that could
play a role in refraining the development of HAM/TSP disease among HTLV-1 infected popu-
lation. Rapid and extensive westernization improved the socioeconomic level of the Marti-
nique population and was followed by sanitary changes to the environment. Sanitation and
hygienic behavior improvements resulted in a rapid reduction in parasite infection. Between
1978 and 1994, the intestinal parasitism in children decreased from 70% to 8% [24]. Few stud-
ies, with divergent conclusions, focused on HAM/TSP development and parasite infection.
Whereas a study assume that Schistosoma proteins may reduce inflammatory process associ-
ated with HTLV-1 infection through interferon-gamma level decrease [25], another one report
that treatment of helminthic infection does not affect the risk of HAM/TSP development [26].
Gillet et al. [27] suggest that co-infection with Strongyloides is associated with formation of
new HTLV-1-infected T-cell clones and with oligoclonal proliferation of certain HTLV-1
clones, increasing thereby the risk of HTLV-1 disease expression. On the other hand, whereas
HTLV-1 and Strongyloides infect 43% and 35% of tested indigenous in Central Australia [28],
the HAM/TSP prevalence appears very low in these communities with extremely poor access
to sanitation and hygiene facilities [29]. Studies are still needed to investigate the role of a
potential co-factor associated with sanitary change and potentially leading to decline in num-
ber of HAM/TSP diagnosis. The present study does not allow reliable conclusions about the
synergistic effects of HTLV-1 transmission prevention programs and improvement of sanitary
conditions in HAM/TSP incidence rates decline from 2001 in Martinique.
Whereas meta-analyses show no clear evidence that structural interventions at community
level, to increase condom use, prevent the transmission of HIV and other sexually transmitted
infections [30], no reliable study has focused on HTLV-1 infection. We assume that HTLV-1
sexual transmission is probably the next challenge in Martinique to continue HTLV-1 sero-
prevalence decrease. Prevention strategies focusing on sexual transmission have to be intensi-
fied and should lead to increase acceptability of condom in the general population using mass
media campaigns, public opinion, meeting’s school information and social marketing adver-
tisement; improve condom accessibility particularly for low-income population; improve
female access to condom; extend the availability of condoms such as condom machine installa-
tion in public and private spaces.
Despite the large study period of 25 years, the number of new HAM/TSP cases remains lim-
ited with low statistical power particularly in comparing the characteristics of the two groups
of patients with a disease onset before and after 2001. Between 1986 and 2015, technological
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improvement of imaging and laboratory investigations may have influenced HAM/TSP diag-
nosis accuracy. However, HAM/TSP diagnosis criteria did not change during the study time
and imaging methods that are crucial to rule out alternative myelopathy and especially spinal
cord compression, were available through the whole study time. A reduction of HAM/TSP
patients referred to our network by the primary health setting over the study period might be
raised. However, only slight changes occurred to the global health care network for HTLV-1
infected patients. Moreover, we assume that improvement of medical management of HAM/
TSP patients in Neurology and Rehabilitation centers may have prompted general practition-
ers and primary care centers to refer more systematically patients to our network. We showed
that HTLV-1 seroprevalence have decreased over 20 years among first-time blood donors, but
the absence of demographic characteristics of this population limits our findings
interpretation.
In summary, Martinique faces a rapid and sustained decline of HAM/TSP incidence from
2001 estimated by 70% in comparison to 1986–2000 periods. Implementation of HTLV-1
transmission prevention strategy may result in seroprevalence reduction and in HAM/TSP
incidence decrease observed 15 years later. The monitoring of new HAM/TSP cases has to be
continued and HTLV-1 seroprevalence in blood donors and pregnant women must be sequen-
tially assessed.
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